newsfilter
← Latest News
ClinicalTrials.gov·

COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study - NCT05518487

The proportion of participants who reach a SARS-CoV-2 S antibody level >5000 U/mL, Composite that includes death, graft loss, need for dialysis, and acute rejection, Death, (and 19 more...)